Mistletoe treatments for minimising side effects of anticancer chemotherapy
A-M, Velasco Garrido, Busse
200,000 persons died in 2002 in Germany as a consequence of cancer
diseases. Cancer (ICD-9: 140-208, ICD-10: C00-C97) accounted for 28%
of all male deaths and for 22% of all female deaths. Cancer treatment
consists on surgery, radio- and chemotherapy. During chemotherapy
patients may experience a wide variety of toxic effects (including
life-threatening toxicity) which require treatment. The type and the
intensity of chemotherapy toxicity are one of the limiting factors in
cancer treatment. Toxic effects are also one of the factors affecting
health related quality of life (HRQOL) during chemotherapy.
Mistletoe extracts belong to the group of so called „unconventional methods“ and are used in Germany as complementary cancer treatments. It has been postulated that the addition of mistletoe to chemotherapeutical regimes could help reduce chemotherapy-induced toxicity and enhance treatment tolerability.
The German social health insurance covers the prescription of ML I standardized mistletoe extracts when those are prescribed as palliative cancer treatments with the aim of improving HRQOL.
- Does the addition of mistletoe to chemotherapeutical regimes reduce their toxicity?
- Does the addition of mistletoe to chemotherapeutical regimes contribute to improve quality of life?
- Has the addition of mistletoe to chemotherapeutical regimes any effects on survival?
- Has the addition of mistletoe to chemotherapeutical regimes any effects on tumor-remission?